Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that
redirect T cells to tumor surface antigens. While efficacious against certain hematological …

While chemotherapy and radiotherapy remain the first-line approaches for the management
of most unresectable tumors, immunotherapy has emerged in the past two decades as a …

Abstract CDK4/6 inhibitors (CDK4/6i) and oncolytic viruses are promising therapeutic agents
for the treatment of various cancers. As single agents, CDK4/6 inhibitors that are approved …

Gene therapy is currently in the public spotlight. Several gene therapy products, including
oncolytic virus (OV), which predominantly replicates in and kills cancer cells, and COVID-19 …

Simple Summary Current cancer therapies are insufficient to cure advanced malignancies
and cause off-target toxicity. Scientists have focused on developing new, more efficacious …

Inducing a full antitumor immune response in the tumor microenvironment (TME) is essential
for successful cancer immunotherapy. Here, we report that an oncolytic adenovirus carrying …

Simple Summary Cancer rates have been accelerating significantly in recent years. Despite
notable advances having been made in cancer therapy, and numerous studies being …

Cancer is among the major leading causes of mortality globally, and chemotherapy is
currently one of the most effective cancer therapies. Unfortunately, chemotherapy is …

Oncolytic viruses (OVs) represent a novel class of cancer immunotherapy agents that
preferentially infect and kill cancer cells and promote protective antitumor immunity …

Simple Summary Oncolytic adenoviruses are genetically engineered to selectively replicate
within cancer cells by exploiting their unique characteristics while sparing normal cells …